<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01111253</url>
  </required_header>
  <id_info>
    <org_study_id>09/233</org_study_id>
    <secondary_id>2009-015004-26</secondary_id>
    <secondary_id>NL29615.018.09</secondary_id>
    <secondary_id>ABR 29615</secondary_id>
    <secondary_id>80-82310-97-10039</secondary_id>
    <secondary_id>WO 08-54</secondary_id>
    <nct_id>NCT01111253</nct_id>
  </id_info>
  <brief_title>Diverticulitis: Antibiotics or Close Observation?</brief_title>
  <acronym>DIABOLO</acronym>
  <official_title>DIABOLO Trial: A Multicenter Randomized Clinical Trial Investigating the Cost-effectiveness of Treatment Strategies With or Without Antibiotics for Uncomplicated Acute Diverticulitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dutch Digestive Diseases Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale

      The prevalence of colonic diverticular disease is increasing in Western countries.
      Approximately 10 to 25% of patients with diverticular disease will eventually develop an
      episode of acute diverticulitis. Currently conservative treatment often includes antibiotic
      therapy. This advice lacks sound evidence and is merely based on experts' opinion. An old
      clinical dogma is being clarified with this randomized trial.

      Objective

      Primary objective is to evaluate whether or not using antibiotics reduces to time to full
      recovery of an attack of uncomplicated (mild) diverticulitis. Secondary objectives are to
      evaluate complications, quality of life, readmission rate, recurrence rate, medical and
      non-medical costs, and antibiotic resistance/sensitivity in both groups.

      Hypothesis

      The investigators hypothesis is that in the treatment of uncomplicated (mild) acute
      diverticulitis, supportive treatment without antibiotics is a more cost-effective approach
      than conservative treatment with antibiotics with respect to time-to-recovery as primary
      outcome.

      Study design

      A randomized, open label, multicenter clinical trial comparing treatment of acute
      uncomplicated diverticulitis with antibiotics to observation and supportive care alone.

      Study population

      Patients 18 years or older are eligible for inclusion if they have a diagnosis of acute
      uncomplicated diverticulitis as demonstrated by imaging. Only patients with stages 1a and 1b
      according to Hinchey's classification or &quot;mild&quot; diverticulitis according to the Ambrosetti
      criteria are included.

      Intervention

      Conservative strategy with antibiotics: supportive measures and at least 48 hours of
      intravenous antibiotics (and therefore admittance to the hospital) and subsequently switch to
      oral antibiotics if tolerated (total duration of 10 days).

      Control

      Liberal strategy without antibiotics: supportive measures only. Observation and oral intake
      as tolerated. Admittance only if discharge criteria are not met on presentation.

      Main study parameters/endpoints

      The primary endpoint is time-to-recovery with a 6-month follow-up period. Secondary endpoints
      are occurrence of complicated diverticulitis requiring surgery or percutaneous treatment,
      morbidity, health related quality of life, readmission rate, recurrence rate, medical and
      non-medical costs, and antibiotic resistance/sensitivity.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2010</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time-to-full-recovery</measure>
    <time_frame>6 months follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Direct medical costs</measure>
    <time_frame>6 months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of complicated diverticulitis defined as abscess, perforation, stricture and/or fistula and need for percutaneous drainage and/or operation</measure>
    <time_frame>24 months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predefined side-effects of initial antibiotic treatment</measure>
    <time_frame>24 months follow-up</time_frame>
    <description>e.g. antibiotic resistance/sensitivity pattern, allergy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity, like urinary tract infection, pneumonia, etc</measure>
    <time_frame>24 months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>24 months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmission rate</measure>
    <time_frame>6 months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indirect medical costs</measure>
    <time_frame>6 months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute diverticulitis recurrence rate</measure>
    <time_frame>12 months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute diverticulitis recurrence rate</measure>
    <time_frame>24 months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health status</measure>
    <time_frame>3 months follow-up</time_frame>
    <description>Changes and valuation over time (compared to t=0) will be measured using generic and disease specific quality of life questionnaires (Euro-Qol 5D, Short Form 36 (SF-36) and the Gastro-intestinal Quality of Life Index (Giqli))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health status</measure>
    <time_frame>6 months follow-up</time_frame>
    <description>Changes and valuation over time (compared to t=0 and 3 months) will be measured using generic and disease specific quality of life questionnaires (Euro-Qol 5D, Short Form 36 (SF-36) and the Gastro-intestinal Quality of Life Index (Giqli))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health status</measure>
    <time_frame>12 months follow-up</time_frame>
    <description>Changes and valuation over time (compared to t=0, 3 and 6 months) will be measured using generic and disease specific quality of life questionnaires (Euro-Qol 5D, Short Form 36 (SF-36) and the Gastro-intestinal Quality of Life Index (Giqli))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health status</measure>
    <time_frame>24 months follow-up</time_frame>
    <description>Changes and valuation over time (compared to t=0, 3, 6 and 12 months) will be measured using generic and disease specific quality of life questionnaires (Euro-Qol 5D, Short Form 36 (SF-36) and the Gastro-intestinal Quality of Life Index (Giqli))</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">533</enrollment>
  <condition>Diverticulitis</condition>
  <arm_group>
    <arm_group_label>Conservative strategy with antibiotics</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hospital admission
Intravenous fluids and at least 48 hours of intravenous antibiotics and subsequently switch to oral antibiotics if tolerated (otherwise continuation i.v.) to complete a full 10-day treatment duration
Adequate pain relief
Oral intake as tolerated
Daily monitoring</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liberal strategy without antibiotics</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Admission only if discharge criteria are not met
No initial antibiotics
Intravenous fluids only for those not tolerating oral liquids
Adequate pain relief
Oral intake as tolerated
Daily monitoring when admitted to the hospital
Self-monitoring at home (Patient diary with temperature and VAS pain score until full recovery)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin-clavulanate</intervention_name>
    <description>Amoxicillin-clavulanate: 4 times a day 1200 mg and switch to oral administration 3 times a day 625 mg after two days, for a total duration of 10 days.
In case of allergy to Amoxicillin-clavulanate: intravenous administration ciprofloxacin 2 times a day 400 mg and metronidazole 3 times a day 500 mg. In case of oral administration ciprofloxacin 2 times a day 500 mg and metronidazole 3 times a day 500 mg. For a total duration of 10 days.</description>
    <arm_group_label>Conservative strategy with antibiotics</arm_group_label>
    <other_name>Augmentin.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Only left-sided uncomplicated (mild) acute diverticulitis;

          -  Clinical suspicion of acute diverticulitis. For acute diagnostic work-up: ultrasound
             or CT proven diverticulitis. In the case of diverticulitis-negative ultrasound in
             clinically suspected patients an intravenous contrast-enhanced CT scan is mandatory
             for confirmation of diverticulitis or exclusion of other pathology. CT for
             Hinchey/Ambrosetti classification (which is a CT-based classification system) is
             needed for all patients, but can be delayed 1 day in those with ultrasound diagnosis.
             Staging diverticulitis is defined according the modified Hinchey/Ambrosetti staging,
             only stages 1a and 1b and &quot;mild&quot; diverticulitis (1a Confined pericolic inflammation,
             1b Confined small (smaller than 5cm) pericolic abscess) are included;

          -  All patients with informed consent.

        Exclusion Criteria:

          -  Previous radiological (ultrasound and/or CT) proven episode of diverticulitis;

          -  Colonic cancer;

          -  Inflammatory bowel disease (ulcerative colitis, Crohn's disease);

          -  Hinchey stages 2, 3 and 4 or &quot;severe&quot; diverticulitis according to the Ambrosetti
             criteria, which require surgical or percutaneous treatment;

          -  Disease with expected survival of less than 6 months;

          -  Contraindication for the use of the study medication (e.g. patients with advanced
             renal failure or allergy to antibiotics used in this study);

          -  Pregnancy, breastfeeding;

          -  ASA (American Society of Anaesthesiologists) classification &gt; III;

          -  Immunocompromised patients;

          -  Clinical suspicion of bacteraemia (i.e. sepsis);

          -  The inability of reading/understanding and filling in the questionnaires;

          -  Antibiotic use in the 4 weeks before admittance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie A Boermeester, MD, PhD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ziekenhuisgroep Twente</name>
      <address>
        <city>Almelo</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flevo Hospital</name>
      <address>
        <city>Almere</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meander Hospital</name>
      <address>
        <city>Amersfoort</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BovenIJ Hospital</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sint Lucas Andreas Hospital</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Slotervaart Hospital</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VU Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gelre Hospitals</name>
      <address>
        <city>Apeldoorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rijnstate Hospital</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rode Kruis Hospital</name>
      <address>
        <city>Beverwijk</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reinier de Graaf Gasthuis</name>
      <address>
        <city>Delft</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Schweitzer Hospital</name>
      <address>
        <city>Dordrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kennemer Hospital</name>
      <address>
        <city>Haarlem</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuisgroep Twente</name>
      <address>
        <city>Hengelo</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tergooi Hospital</name>
      <address>
        <city>Hilversum</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spaarne Hospitals</name>
      <address>
        <city>Hoofddorp</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westfries Gasthuis</name>
      <address>
        <city>Hoorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sint Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ikazia Hospital</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sint Franciscus Gasthuis</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Máxima Hospital</name>
      <address>
        <city>Veldhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.diabolo-trial.nl</url>
    <description>DIABOLO trial website</description>
  </link>
  <reference>
    <citation>de Korte N, Unlü C, Boermeester MA, Cuesta MA, Vrouenreats BC, Stockmann HB. Use of antibiotics in uncomplicated diverticulitis. Br J Surg. 2011 Jun;98(6):761-7. doi: 10.1002/bjs.7376. Epub 2011 Jan 6. Review.</citation>
    <PMID>21523694</PMID>
  </reference>
  <reference>
    <citation>de Korte N, Kuyvenhoven JP, van der Peet DL, Felt-Bersma RJ, Cuesta MA, Stockmann HB. Mild colonic diverticulitis can be treated without antibiotics. A case-control study. Colorectal Dis. 2012 Mar;14(3):325-30. doi: 10.1111/j.1463-1318.2011.02609.x.</citation>
    <PMID>21689302</PMID>
  </reference>
  <reference>
    <citation>de Korte N, Klarenbeek BR, Kuyvenhoven JP, Roumen RM, Cuesta MA, Stockmann HB. Management of diverticulitis: results of a survey among gastroenterologists and surgeons. Colorectal Dis. 2011 Dec;13(12):e411-7. doi: 10.1111/j.1463-1318.2011.02744.x.</citation>
    <PMID>21819518</PMID>
  </reference>
  <reference>
    <citation>Unlü C, de Korte N, Daniels L, Consten EC, Cuesta MA, Gerhards MF, van Geloven AA, van der Zaag ES, van der Hoeven JA, Klicks R, Cense HA, Roumen RM, Eijsbouts QA, Lange JF, Fockens P, de Borgie CA, Bemelman WA, Reitsma JB, Stockmann HB, Vrouenraets BC, Boermeester MA; Dutch Diverticular Disease 3D Collaborative Study Group. A multicenter randomized clinical trial investigating the cost-effectiveness of treatment strategies with or without antibiotics for uncomplicated acute diverticulitis (DIABOLO trial). BMC Surg. 2010 Jul 20;10:23. doi: 10.1186/1471-2482-10-23.</citation>
    <PMID>20646266</PMID>
  </reference>
  <reference>
    <citation>Draaisma WA, van de Wall BJ, Vermeulen J, Unlu C, de Korte N, Swank HA. [Treatment for diverticulitis not thoroughly researched]. Ned Tijdschr Geneeskd. 2009;153:A648. Review. Dutch.</citation>
    <PMID>19857313</PMID>
  </reference>
  <reference>
    <citation>Ünlü C, Daniels L, Vrouenraets BC, Boermeester MA. A systematic review of high-fibre dietary therapy in diverticular disease. Int J Colorectal Dis. 2012 Apr;27(4):419-27. doi: 10.1007/s00384-011-1308-3. Epub 2011 Sep 16. Review.</citation>
    <PMID>21922199</PMID>
  </reference>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2010</study_first_submitted>
  <study_first_submitted_qc>April 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2010</study_first_posted>
  <last_update_submitted>October 26, 2012</last_update_submitted>
  <last_update_submitted_qc>October 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>M.A. Boermeester</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>multicenter randomized, open label, clinical trial</keyword>
  <keyword>acute uncomplicated (mild) diverticulitis</keyword>
  <keyword>treatment strategies</keyword>
  <keyword>management of diverticulitis</keyword>
  <keyword>antibiotics</keyword>
  <keyword>observation and supportive care</keyword>
  <keyword>cost analysis</keyword>
  <keyword>economic evaluation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diverticulitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>July 3, 2017</submitted>
    <returned>November 28, 2017</returned>
    <submitted>January 9, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

